ENTX Stock Surges 87% Following Massive Breakout Momentum

tera Bio (NASDAQ: ENTX) ripped roughly 87% on July 27, 2026, closing near $3.83 after a gap-and-go session that triggered an aggressive bid the moment the prior range cracked, according to a breakdown from StocksToTrade. This is the kind of name where the chart does all the talking, and on Monday it shouted: thin biotech float, strong cash cushion, and zero revenue anchoring valuation. For scalpers, that combination is a loaded gun — fast in both directions.

The Setup That Triggered the Move

ENTX spent weeks compressing inside roughly $1.60–$2.05 on the daily chart. Tight ranges on muted volume are absorption zones — sellers get paid, buyers accumulate, and volatility decays until it doesn't. You watch the edges. When price holds the low $2s on multiple tests without flushing, the range is coiling. The breakout came on July 27, 2026: ENTX gapped from the low $2s into the $3s in premarket around 08:30, briefly tapped $3.92, then settled into the open near $2.77. That early dip is the shakeout — weak hands flushed before the real bid stepped in. From there it was higher lows, stronger closes, and a finish at the highs of the day. That's textbook momentum continuation structure: gap, washout, reclaim, trend.

Execution Levels That Matter Now

The prior multi-week range — roughly $1.60 to $2.05 — is now your invalidation zone for any long bias. Above $3, momentum controls the tape. If you're fading strength, the trigger is a clean loss of the $3 area on rising volume; that signals buyers are exhausted and the gap is closing. If you're trading continuation, the playbook is red-to-green off the prior day's low or a flag-pullback to the breakout zone near $2.96–$3.10. Either way, you respect the spread — this is a small-cap biotech with around $11.98M in cash and minimal revenue, so liquidity gaps appear without warning.

Risk Rules for the Next Session

If ENTX opens above $3.80 and holds the first five-minute high, momentum is still feeding you — trail tight, don't predict a top. If it gaps down below $3, treat it as a failed continuation until proven otherwise; the prior range ceiling near $2.05 is now the line in the sand. Position size smaller than you think. The fundamentals — ~$42K in revenue against ~$3.5M in quarterly operating losses — haven't changed; this is a catalyst and tape-read trade, not a valuation trade. Manage the move, don't marry it.